Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity is a research paper published in Cancer Cell (2022). On theSindex it has a DataRank of 3.9. It has been cited 106 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.701
From this paper's citation signal
Citation Network Contribution
3.2
From 84 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Institutes of Health
Grant: 5R01CA234183-05
Therapeutic strategies against EGFR exon 20 mutant lung cancer
National Institutes of Health
Grant: 1U54CA224065-01
University of Texas PDX Development and Trial Center
National Institutes of Health
Grant: 5R01CA190628-03
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing
National Institutes of Health
Grant: 5R01CA247975-02
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors
National Institutes of Health
Grant: 3P50CA070907-02S1
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCER
Fields of Study
Keywords
Sustainable Development Goals